Neuralink Launches Human Trials for Brain Implants
Neuralink has begun clinical trials of its brain-computer technology on individuals with disabilities. Participants will receive compensation for all expenses, including transportation.
Neuralink has started clinical trials of its brain-computer interface technology on human patients. The innovation offers people with severe disabilities the ability to control external devices using only their thoughts.
It holds the potential to transform the lives of individuals living with paralysis, blindness, or speech impairments.
Moreover, Neuralink will also cover all related costs for participants, including travel, accommodation, and other expenses.
The company has opened registration for participants in its clinical trials. However, eligibility is currently limited to individuals with the following conditions:
- Quadriplegia
- Paraplegia
- Visual impairments
- Speech disorders
In addition, candidates must be over 18 years old to participate.
The trial began after receiving approval from the FDA in September 2023. Currently, only three participants have been approved for the brain-computer technology implantation. The technology is designed to assist individuals with disabilities, enhancing their ability to interact with the external world.
Neuralink is actively supporting participation from people around the world, intending to improve quality of life and expand opportunities for those with disabilities.
Related: Neuralink and Beyond: Sci-Fi Concepts Becoming Reality
Neuralink's Goals, Future Technology, and Ethical Considerations
Neuralink's long-term goal is to develop a strong connection between the human brain and artificial intelligence. This technology has the potential to provide cybernetic enhancements, including superhuman intelligence and enhanced perception.
In the future, it could significantly expand human capabilities and change how we interact with the world.
However, the use of Neuralink raises ethical concerns, especially regarding animal testing. Controversy has arisen due to reports of more than 1,500 animal deaths during the trials. Some experts question the potential health risks for humans and the long-term consequences of the technology.
Despite the criticism, Neuralink continues its work, operating within the standards approved by regulatory bodies, and is focused on minimizing ethical risks to ensure that biohacking benefits humanity.
The content on The Coinomist is for informational purposes only and should not be interpreted as financial advice. While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, or reliability of any content. Neither we accept liability for any errors or omissions in the information provided or for any financial losses incurred as a result of relying on this information. Actions based on this content are at your own risk. Always do your own research and consult a professional. See our Terms, Privacy Policy, and Disclaimers for more details.
Articles by this author
